中国药物经济学
中國藥物經濟學
중국약물경제학
CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS
2014年
5期
33-35
,共3页
黄连素%双歧杆菌三联活菌%慢性腹泻
黃連素%雙歧桿菌三聯活菌%慢性腹瀉
황련소%쌍기간균삼련활균%만성복사
Berberine%Triple viable bifidobacterium%Chronic diarrhea
目的:评价双歧杆菌三联活菌联合黄连素治疗慢性腹泻的临床疗效和复发率。方法将120例慢性腹泻患者随机分为应用双歧杆菌三联活菌联合黄连素治疗的观察组、应用左氧氟沙星联合黄连素治疗的对照组,观察两组治疗3周后的疗效及1年复发率,并进行比较。结果观察组总有效率为96.7%,对照组总有效率为78.3%,观察组总有效率明显优于对照组(P<0.05);观察组1年复发率为25.9%,对照组1年复发率为42.6%,差异有统计学意义(P<0.05);两组患者均未发现明显不良反应。结论双歧杆菌三联活菌联合黄连素治疗慢性腹泻安全、有效,复发率低。
目的:評價雙歧桿菌三聯活菌聯閤黃連素治療慢性腹瀉的臨床療效和複髮率。方法將120例慢性腹瀉患者隨機分為應用雙歧桿菌三聯活菌聯閤黃連素治療的觀察組、應用左氧氟沙星聯閤黃連素治療的對照組,觀察兩組治療3週後的療效及1年複髮率,併進行比較。結果觀察組總有效率為96.7%,對照組總有效率為78.3%,觀察組總有效率明顯優于對照組(P<0.05);觀察組1年複髮率為25.9%,對照組1年複髮率為42.6%,差異有統計學意義(P<0.05);兩組患者均未髮現明顯不良反應。結論雙歧桿菌三聯活菌聯閤黃連素治療慢性腹瀉安全、有效,複髮率低。
목적:평개쌍기간균삼련활균연합황련소치료만성복사적림상료효화복발솔。방법장120례만성복사환자수궤분위응용쌍기간균삼련활균연합황련소치료적관찰조、응용좌양불사성연합황련소치료적대조조,관찰량조치료3주후적료효급1년복발솔,병진행비교。결과관찰조총유효솔위96.7%,대조조총유효솔위78.3%,관찰조총유효솔명현우우대조조(P<0.05);관찰조1년복발솔위25.9%,대조조1년복발솔위42.6%,차이유통계학의의(P<0.05);량조환자균미발현명현불량반응。결론쌍기간균삼련활균연합황련소치료만성복사안전、유효,복발솔저。
Objective To observe the clinical ef icacy of berberine Chapeifeikang combination treatment of chronic diarrhea and recurrence rate.Methods 120 patients with chronic diarrhea were randomly divided into observation group Triple viable bifidobacterium joint berberine,Berberine levofloxacin combined control group,60 cases in each group,the last three weeks of treatment,ef icacy and recurrence rates after one year,and for comparison.Results The study group triple viable bifidobacterium berberine combined total ef iciency of 96.7%,levofloxacin berberine combined total ef iciency of the control group was 78.3%,the total ef iciency of the observation group than the control group(P<0.05);1-year recurrence rate in the observation group of 25.9%,1-year recurrence rate of 42.6% in the control group,the dif erence was statistical y significant(P<0.05);groups of patients found no significant adverse reactions.Conclusion Triple viable bifidobacterium berberine combined treatment of chronic diarrhea safe,ef ective, low recurrence rate,worthy of clinical use.